Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I fear you are not doing an efficient search job. To begin with I would suggest searching clinicaltrials.gov by the advanced search on sponsor "delcath".
For many months, I believe the only clinical trial recruiting in the United States is ocular melanoma. The other trial that may say recruiting is just a European registry, not really a trial.
That message which does not surprise me does not suffice. I believe the ONLY trial recruiting currently is OM. Do you have that understanding?
Since I believe Simpson is a straight shooter on the clinical trials, my concern is enrollment issues which could be entirely legit but ugly and hidden from view. For now, being a percentage guy 75 percent chance phase 3 successfully ended by end of 2019.
Give note to the fact that funding issues have had a negative impact on the trial.
It would be nice to see the results of offering this very week, my current guess is .006 which could be seen as terrible, but 2nd offering will be a guess all its own
That did happen to delcath for a month in 2007 due to associated deaths. It seems this generation 2 product with improved procedures has been a champ on safety, with easily addressed side effects.
I have more confidence in Simpson than vast majority. How these offerings go is a guess but there will be lots of dilution in 2018 and 2019, but a good sign would be this offering done fast
Ten little indian thinking. After this offering is filled, what will they do? Hold the price steady for next offering. 50/50 on that
If .005 steady would be $2.50
Time to repeat my most objective statement over a 64 year lifetime. Sum total of shareholder posters here = chaos = zero, reader BEWARE
I sort of understand if the $20 million is all financed at a similar price. Then the $4.6 million done before is maybe a mild sacrifice play as warrants probably help some.
It is beyond my understanding though if it turned into a bunch of descending stepping stones. If this offering goes at .005 then the following offering or offerings in 2018 need to be for approximately $2.50 to make sense. Of course as Rap would dream, if they go for $10 then better yet
Are most of you beyond help? The current outstanding shares is less than 1 million post split.
Your warrant connection is baseless. Companies have outstanding warrants all the time. Delcath fixed their shortage of shares with the affirmative votes. 500 M pre split is nothing, how hard is that to understand
You need to drop that business, the warrant situation is totally fixed, so that theory is sleeping comfortably on boot hill
Please it looked more like 3 cents over all, faulty memories always excel.
Based on history and today, my guess would be 1/2 of 1 cent
It might drift down to .04 before reverse split and at split, open at $2. On the other hand, it could be higher than $2
at least similar, they plan to make money, of that 100 percent plan
Nope. I am not confident of the best strategy but it is logical to put to use shares. 500 million shares pre rs represents 1 million of 999 million empty slots coming up. After this offering there will be 1.5 billion warrants pre rs, for another 3 million of 999 million empty
So at point of rs, there will be outstanding less than 2 million shares along with 3 million warrants. Empty slots remaining over 995 million, hopefully vast majority never needed
It is simple that delcath can expand shares tremendously which is the fear. They could expand between auth and rs, 1000 fold the number of shares, but worst case I hope is by mid 2019 the share count will have grown no more than 100 fold from the current 400 plus million.
I certainly think will be at least 20 fold, but with those warrants executed the company could be loaded with cash in mid 2019. They will need some to do an expensive submission to the FDA as well as continue I hope a thriving ICC phase 3 trial
Current market cap approx. $3 million
If share count is up 20 fold by mid 2019 and current equivalent price, market cap would be $60 million
This is not rocket science, is it? There are 1 billion shares authorized. The new shares and warrants, don't use those figures for this. Think ahead. Divide those by 500
I don't believe 1/10 of 1 ounce of what is mostly said on this message board. The simple question is there money to be made by astute little retail here. I think so, but the way will probably not be clear until at least the next offering
Please another 1 billion shares before a reverse split is only 2 million shares. The company is rolling in loads of shares that only a horrifying convertible would probably be capable of exceeding.
The shorting myth needs to end. The YES voters bought at 2 cents, shorting would not have made money for them. This is a mystery operation right now by Roth and Delcath, put on a real THINKING cap.
If we don't get one cent on this offering the mystery is well described and I think sadly one half cent is more achievable.
I don't think Trompete tries to forecast the company except where his point is relevant, who would want delcath? 100 percent believer that nobody will show interest in first half of 2018 and maybe never, ever never. Even if they did, it has only lost speculators on that big money so far with no clear end in sight
There will be at least one more financing after this one for 2018 and it may be still in first half of year.
This financing needs one cent per unit to lighten the mood. Otherwise the mood will remain dark until again the company is measured on the next financing.
That was in relation to $3 or the range I was suggesting of $1 to $3.
$3 divided by 500 = .006. I am skeptical with the approach we are now seeing. I would feel much better if units achieve 1 cent. 1/2 of a cent may be more likely
I assume the authorized was immediate, so yes this would be the fast way to get more money and possibly better, because it delays a possible price drop due to reverse split. Have to see the execution. As I said .006 or better would be on the high end compared to reverse split offering.
I fully expected the warrants for 2 shares to be in unit, no surprise there
I was totally fooled. They are going to do an offering based on the authorized increase first. Then they are going to do a reverse split. Then they will raise more money.
If the units sell for more than .006, it will beat my $3.00 best case.
The offering may spell more of the same, or change of stripes. One fell swoop of near $20 million at a fixed price is a very big deal for the future, it that is how the cards play
Hopefully approaching the 12 month countdown to end of phase 3. When the market is efficient, it thinks AHEAD
I would suggest the lack of accurate memories, bad interpretations, excessive condemnation can only lead ever so many astray here
Death spiral, if there was ever a time it is likely to end, I predict it is now with a bust out of the death spiral. I predict next 18 months are going to look good, the near term bottom post rs likely $1.00 to $3.00
No, she never said it was approved in the 2 previous
2 cents was a disappointment but most signals were for 3 cents. My belief is this saves the company and makes money for roth clients. We have to trade wisely, I am trying on that
Also you are intentionally misleading, the warrants are not free shares
Yes, I believe Simpson engineered a straight victory vote, the offering supporters whoever they may be, approved 100 percent and Roth may have even been the true engineer of the whole plan
The press release seems clear enough to me. This message board is terribly weak as a source of info.
Plz see Pedder as a jovial guy that enjoys collecting money from companies for little work in return
I predict fast reverse split and fast offering, 60 percent chance Roth comes out with guns blazing with up to $20 million raised. After that a Roth analyst will then tout this company and the phase 3
Almost DOUBLE on YES for RS, shocking
But you don't know, who holds the warrants, 10 Indians I say
Do stripes change or not? 3rd time for a vote was the charm. Only relevant if the analogy can be extended further
People with lots of money voted YES, who be they, 10 Indians I think
there are listed sites and contact information for the phase 3 trial. No mystery but probably you have to be a legitimate medical cancer contact, I am guessing that is the way potential patients are channeled to a site.
Besides delcath already has a history of a completed phase 3 trial. They are not messing around, it is obvious FDA and delcath have a working relationship.
Prove you are a serious scientist and/or analyst to continue down this path. The burden again is on you and your allies if they reveal themselves
That is the one of the problems with always blaming, accusing, and fault finding the company. The product is worthy of usage, but it is debatable for commercial purposes. Any product with such a rough start in Europe should have the tires kicked.
Also jumping from OM usage to all of liver cancer, that is 2010 type thinking not appropriate for 2018
That is a very strong argument against buyout. If Roth or another financial party decides to back delcath, commercial potential is not relevant in 2018.
Over 90 percent of your posts are against management, that is your strongest argument since everybody seems to agree
Born backward lookers in control, it works looking backwards some of the time. Admit your forward guide is stuck on backward view